233 related articles for article (PubMed ID: 7649195)
1. Comparative activity of selected antiviral compounds against clinical isolates of varicella-zoster virus.
Andrei G; Snoeck R; Reymen D; Liesnard C; Goubau P; Desmyter J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1995 Apr; 14(4):318-29. PubMed ID: 7649195
[TBL] [Abstract][Full Text] [Related]
2. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
3. Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment.
Snoeck R; Andrei G; De Clercq E
Drugs; 1999 Feb; 57(2):187-206. PubMed ID: 10188760
[TBL] [Abstract][Full Text] [Related]
4. Antiviral activity of selected acyclic nucleoside analogues against human herpesvirus 6.
Reymen D; Naesens L; Balzarini J; Holý A; Dvoráková H; De Clercq E
Antiviral Res; 1995 Dec; 28(4):343-57. PubMed ID: 8669893
[TBL] [Abstract][Full Text] [Related]
5. Analysis of phosphorylation pathways of antiherpesvirus nucleosides by varicella-zoster virus-specific enzymes.
Koyano S; Suzutani T; Yoshida I; Azuma M
Antimicrob Agents Chemother; 1996 Apr; 40(4):920-3. PubMed ID: 8849252
[TBL] [Abstract][Full Text] [Related]
6. In vitro-selected drug-resistant varicella-zoster virus mutants in the thymidine kinase and DNA polymerase genes yield novel phenotype-genotype associations and highlight differences between antiherpesvirus drugs.
Andrei G; Topalis D; Fiten P; McGuigan C; Balzarini J; Opdenakker G; Snoeck R
J Virol; 2012 Mar; 86(5):2641-52. PubMed ID: 22190713
[TBL] [Abstract][Full Text] [Related]
7. Susceptibilities of several clinical varicella-zoster virus (VZV) isolates and drug-resistant VZV strains to bicyclic furano pyrimidine nucleosides.
Andrei G; Sienaert R; McGuigan C; De Clercq E; Balzarini J; Snoeck R
Antimicrob Agents Chemother; 2005 Mar; 49(3):1081-6. PubMed ID: 15728906
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy of varicella zoster virus infections.
Snoeck R; Andrei G; De Clercq E
Int J Antimicrob Agents; 1994 Aug; 4(3):211-26. PubMed ID: 18611613
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the thymidine kinase genes from acyclovir-resistant mutants of varicella-zoster virus isolated from patients with AIDS.
Talarico CL; Phelps WC; Biron KK
J Virol; 1993 Feb; 67(2):1024-33. PubMed ID: 8380452
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapy of varicella-zoster virus by a novel class of highly specific anti-VZV bicyclic pyrimidine nucleosides.
Balzarini J; McGuigan C
Biochim Biophys Acta; 2002 Jul; 1587(2-3):287-95. PubMed ID: 12084470
[TBL] [Abstract][Full Text] [Related]
11. Meningoradiculoneuritis due to acyclovir-resistant varicella zoster virus in an acquired immune deficiency syndrome patient.
Snoeck R; Gérard M; Sadzot-Delvaux C; Andrei G; Balzarini J; Reymen D; Ahadi N; De Bruyn JM; Piette J; Rentier B
J Med Virol; 1994 Apr; 42(4):338-47. PubMed ID: 8046424
[TBL] [Abstract][Full Text] [Related]
12. Novel agents for the therapy of varicella-zoster virus infections.
Snoeck R; Andrei G; De Clercq E
Expert Opin Investig Drugs; 2000 Aug; 9(8):1743-51. PubMed ID: 11060773
[TBL] [Abstract][Full Text] [Related]
13. Utility of ultra-deep sequencing for detection of varicella-zoster virus antiviral resistance mutations.
Mercier-Darty M; Boutolleau D; Lepeule R; Rodriguez C; Burrel S
Antiviral Res; 2018 Mar; 151():20-23. PubMed ID: 29337163
[TBL] [Abstract][Full Text] [Related]
14. Phenotypic and genetic characterization of varicella-zoster virus mutants resistant to acyclovir, brivudine and/or foscarnet.
Bleymehl K; Cinatl J; Schmidt-Chanasit J
Med Microbiol Immunol; 2011 Aug; 200(3):193-202. PubMed ID: 21373931
[TBL] [Abstract][Full Text] [Related]
15. Antiviral activity of ganciclovir elaidic acid ester against herpesviruses.
Andrei G; Snoeck R; Neyts J; Sandvold ML; Myhren F; De Clercq E
Antiviral Res; 2000 Mar; 45(3):157-67. PubMed ID: 10771080
[TBL] [Abstract][Full Text] [Related]
16. Advances in the treatment of varicella-zoster virus infections.
Andrei G; Snoeck R
Adv Pharmacol; 2013; 67():107-68. PubMed ID: 23886000
[TBL] [Abstract][Full Text] [Related]
17. Comparative activity of various compounds against clinical strains of herpes simplex virus.
Andrei G; Snoeck R; Goubau P; Desmyter J; De Clercq E
Eur J Clin Microbiol Infect Dis; 1992 Feb; 11(2):143-51. PubMed ID: 1327785
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines.
Andrei G; Snoeck R; Piette J; Delvenne P; De Clercq E
Oncol Res; 1998; 10(10):523-31. PubMed ID: 10338155
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory effects of selected antiviral compounds on newly isolated clinical varicella-zoster virus strains.
Baba M; Konno K; Shigeta S; De Clercq E
Tohoku J Exp Med; 1986 Mar; 148(3):275-83. PubMed ID: 3010502
[TBL] [Abstract][Full Text] [Related]
20. Isolation of drug resistant mutants of varicella-zoster virus: cross resistance of acyclovir resistant mutants with phosphonoacetic acid and bromodeoxyuridine.
Shiraki K; Ogino T; Yamanishi K; Takahashi M
Biken J; 1983 Mar; 26(1):17-23. PubMed ID: 6312958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
